747
Views
15
CrossRef citations to date
0
Altmetric
Review

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review

, , , , , , , , & show all
Pages 27-36 | Received 02 Jul 2018, Accepted 28 Aug 2018, Published online: 19 Sep 2018
 

ABSTRACT

Introduction: Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding of the value of DOACs relative to vitamin K antagonists (VKAs).

Areas covered: A systematic literature review was conducted on the available real-world evidence (RWE) of three DOACs (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients with nonvalvular atrial fibrillation (NVAF).This systematic literature review included RWE published up to December 2016. Studies with > 50 patients reporting on incident and prevalent NVAF cases were included. The following databases were searched: Medline, Embase, and the Cochrane Library. Outcomes of interest included thromboembolic events, all-cause mortality, bleeding events, and non-persistence. Of the 562 RWE DOACs articles retrieved, 49 presented results for rivaroxaban versus VKAs, 79 for dabigatran versus VKAs, and 18 for apixaban versus VKAs. Substantial heterogeneity was found across patient population, outcome definition, and follow-up period. Major bleeding, ischemic stroke, and intracranial hemorrhage were the most frequent outcomes analyzed.

Expert commentary: Overall, the RWE studies were aligned with the Phase 3 trials. However, conflicting results were reported for several outcomes of interest.

View correction statement:
Correction

Declaration of Interest

JB Briere, and K Folkerts are employees of Bayer AG; K Bowrin is employee of Bayer Plc. CI Coleman, P Levy and O Wu were paid by Bayer AG as a consultant who provided critical input for the study design and interpretation of results. V Taieb and A Millier are employees of Creativ-ceutical who received funding from Bayer AG. M Toumi was paid by creativ-Ceutical as a consultant who provided critical input for the study design and interpretation of the results.

Reviewer Disclosures

A reviewer on this manuscript has disclosed that they are the CEO and founder of QUALIblood sa and reports personal fees from Stago, Roche Diagnostics, Roche and Daiichi‐Sankyo.

Supplementary material

Supplemental data for this article can be accessed here.

Additional information

Funding

This work was supported by Bayer AG and Creativ-Ceutical, with funding from Bayer AG.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.